Kalorama has the information you need on the drug delivery market, including the needle-free systems, transdermal and transmucosal, and infusion pump segments. Our studies describe the market opportunity, the connection to other medical care channels, and the future direction of the market and its segments. Whether you seek market information for dispensing drugs through intra-arterial, intravenous, subcutaneous, epidural, needle-free jet injector, or other methods, Kalorama has the industry intelligence you need.
- Sort by Product ID
- Display 15 Products per page
Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the effectiveness of PTCA. To improve on this condition, medical science created stents in an attempt to keep coronary arteries open. However, one of the early...Published: May 1, 2003 | Price: $2,062.00 – $4,152.00
The number and scope of drug discovery outsourcing agreements has grown rapidly over the past five years, and the pace will accelerate over the next five years. Outsourcing is now an essential part of drug discovery. Major pharmas and biotechs are aggressively pursuing a range of outsourcing agreements. On the supplier side, smaller vendors rely on outsourcing revenues to pay their bills and boost their credibility. Outsourcing in drug discovery is a popular topic for trade articles and seminars. These...Published: July 18, 2003 | Price: $2,625.00 – $5,250.00
Drug delivery technologies continue to be a vital piece of the pharmaceutical marketing puzzle. From clinical efficacy to product differentiation and life-cycle management, delivery technologies are increasingly demanding the attention of developers at earlier and earlier stages. In Kalorama’s 2001-2002 Drug Delivery series, we focused on the markets by route of administration—oral, injectable, implantable, pulmonary, transdermal etc. In this all new study on advanced drug delivery, however, we focused on drug delivery through the lens of therapeutic application. This report...Published: November 7, 2003 | Price: $746.00 – $1,492.00
Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...Published: November 1, 2004 | Price: $3,500.00 – $7,000.00
The market for pain management products is growing at a brisk pace, with some segments moving ahead at over 20%. The future for specialized pharmaceutical and medical device products in this market is bright and new opportunities exist for emerging treatment modalities as well. The report presents the most up-to-date information about the top-producing pain management products in terms of revenues, and analyzes the market by specific pain sites as well. The report concentrates on the following application areas: Burn...Published: February 18, 2006 | Price: $2,200.00 – $5,990.00
Biopharmaceutical research and development is sure to dramatically increase the number of injectable drugs coming to market over the next few years. While advanced drug delivery techniques continue to hold promise for unique methods of administration, the traditional injection is still the dominant paradigm. However, the staggering costs and intransigent safety problems associated with sharps, along with consumer demand and the move to alternate-site care, are pushing for alternatives to traditional needles and syringes faster than advanced delivery technologies can...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult forecasting projects in market research. In this nearly 500-page analysis, Kalorama Information has compiled all the relevant information about the candidates, their value, and their...Published: May 1, 2006 | Price: $3,550.00 – $7,000.00
This complete re-evaluation of the Men’s Health market focuses on the following prescription drug treatment segments: Men’s Cancer Men’s Sexual Dysfunction Men’s Sexually Transmitted Diseases Men’s Urinary Conditions Andropause The report covers drugs used for the treatment of prostate cancer, testicular cancer, impotence, premature ejaculation, and benign prostatic hyperplasia (BPH), urinary incontinence, and STD’s such as HIV, herpes, and genital warts. For each segment, revenues and forecasts are made by type of drug through 2010; competitive market share of the...Published: October 1, 2006 | Price: $995.00 – $7,000.00
The orthopedic drug market is a highly competitive market and, in some areas, the competitive environment is being shaped by increasing levels of generic competition. Several large pharmaceutical companies compete in the orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are developing or offering products in more niche market areas. For the purposes of this study, the world market for orthopedic drugs has...Published: February 1, 2007 | Price: $2,995.00 – $4,990.00
Fueled by the promise of needle-free mechanisms for vaccine distribution and other pharmaceutical uses, the implantable/injectable drug delivery market is growing rapidly. The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to continued growth. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products. The implantable/injectable delivery drug market is a expected to grow to over $12 billion by 2010. Kalorama’s Drug Delivery Markets. Edition...Published: March 1, 2007 | Price: $2,495.00 – $4,990.00
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality. The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers...Published: April 1, 2007 | Price: $2,495.00 – $4,990.00
New biological treatments are being developed at a record pace, but their potential could be compromised by a significant obstacle: the delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. Kalorama's Drug Delivery Markets Series covers these new systems. The fourth volume of this series, Kalorama's Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Drug Delivery is a complete overview of a delivery mechanism that offers some advantages: low pain, infection risk, fewer...Published: April 1, 2007 | Price: $4,995.00 – $9,990.00
Novel pharmacological and biological approaches to disease are calling for novel systems of delivering therapies. This has focused attention on the market for drug delivery systems and the pharmaceuticals that are sold along with those technologies. Kalorama's Drug Delivery Systems focuses on these technologies. This offer is for the entire 4 volumes of Kalorama's 2nd edition of its Drug Delivery Markets series, covering all major types, including: Oral Delivery Implantable/Injectable Pulmonary Transdermal/Transmucosal While oral delivery remains the most popular and...Published: July 1, 2007 | Price: $2,500.00 – $5,000.00
An understanding of the market for anesthesia could be worthwhile to any pharmaceutical marketer and any equity company investing or consulting in this area. Anesthesia markets are in one sense simple: growth in these drugs are correlated to prevalence and incidence in disease, and the resulting increase in procedure volumes. But as this market continues to grow, increased competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas of the world. New...Published: February 1, 2008 | Price: $995.00 – $7,990.00
Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. All in all, excipients...